Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 13s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Advancements in RP-HPLC: A Review on the Simultaneous Determination of Simvastatin and Celecoxib in Plasma

Gurpreet Kaur*, Aqib Bashir[1], Puja Gulati[2]

*Associate Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab,
Email ID: gurpreet.kaur683@yahoo.com
[1]Research Scholar, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab.
Email ID: buttaakib19@gmail.com
[2]Professor & Principal, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab.
Email ID: Puja_duggal@yahoo.co.in
***Corresponding Author:**
Gurpreet Kaur,
Email ID: gurpreet.kaur683@yahoo.com

Cite this paper as: Gurpreet Kaur, Aqib Bashir, Puja Gulati, (2025) Advancements in RP-HPLC: A Review on the Simultaneous Determination of Simvastatin and Celecoxib in Plasma. *Journal of Neonatal Surgery*, 14 (13s), 188-199.

ABSTRACT

People use simvastatin alongside celecoxib routinely because physicians prescribe these drugs for cardiovascular and inflammatory condition management. Scientists need precise measurement of these drugs in plasma because it enables better therapeutic benefits while reducing unwanted side effects. The analysis of both simvastatin and celecoxib in plasma by Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) undergoes a complete review regarding development and validation, as well as practical implementation. The high sensitivity, along with selectivity and precision characteristics of RP-HPLC, make it an excellent tool for plasma concentration analysis of these drugs. Method development requires optimization of mobile phase composition alongside column selection and detection wavelength, together with flow rate identification. The RP-HPLC method proved suitable for both research and clinical work by validating its performance measures for accuracy, precision, LOD and LOQ, sensitivity and linearity and robustness, and specificity. RP-HPLC stands as an essential technique in the evaluation of drug pharmacokinetics and therapeutic drug monitoring, and drug interaction tests. Visiting RP-HPLC enables researchers to obtain critical data about how simvastatin and celecoxib move through the body through absorption and distribution and metabolism, and elimination (ADME) processes. The data obtained from therapeutic drug monitoring using RP-HPLC allows medical professionals to optimize drug treatment by modifying patient doses based on plasma drug levels. RP-HPLC plays an essential role in the identification of synergistic reactions among medications when patients use several drugs at once. The implementation of RP-HPLC creates several difficulties since it deals with matrix interference and sensitivity problems, and operational limitations. Advancements in column technology combined with mobile phase optimization techniques and modern detection methods via mass spectrometry will significantly improve RP-HPLC utility and accessibility in clinical practice.

Keywords: *RP-HPLC, simvastatin, celecoxib, therapeutic drug monitoring, pharmacokinetics, drug interaction.*

GRAPHICAL ABSTRACT



1. INTRODUCTION

The pharmacological agents Simvastatin and celecoxib serve essential therapeutic functions for different medical disorders.(1) Within the statin class, Simvastatin exists as a lipid-lowering drug that medical professionals prescribe mainly to cardiovascular disease risk patients. HMG-CoA reductase serves as a crucial enzyme for cholesterol biosynthesis, which Simvastatin blocks, reducing the levels of LDL cholesterol in the body.(2) Through its action, simvastatin prevents cardiovascular events, including heart attacks and strokes that develop from elevated cholesterol levels in patients. (3) Selective cyclooxygenase-2 inhibitor celecoxib assists with treating inflammation-based pain symptoms, which occur in arthritis conditions. (4)Through COX-2 enzyme blocking, celecoxib prevents the development of prostaglandins but leaves COX-1 protective functions in stomach tissue intact. Selective COX-2 enzyme blocking in celecoxib produces favorable gastrointestinal outcomes, making it an ideal medication for continuing treatment of osteoarthritis and rheumatoid arthritis.(5) Secondary to combining cardiovascular disease therapy with inflammatory condition management, medical professionals use the prescribed treatment method of simvastatin and celecoxib. The combined usage of these medications presents complications for plasma drug concentration testing, thanks to unknown pharmacokinetic property details. (6)Accurate drug level assessments serve as prerequisites for preventing medication interactions while reaching therapeutic levels that surpass side effect thresholds in treatment optimization. The chemical analysis of simvastatin and celecoxib in plasma needs to start without delay. (7)The drug quantification methods involving spectrophotometry and enzyme-linked immunosorbent assays (ELISA) cannot achieve the required accuracy and reliability for plasma analysis of both medicines. RP-HPLC with reverse phase operation has gained its position as the primary analytical technique because of its advanced separation capabilities that can handle compounds with alike chemical reactivity. PLC enables efficient dual plasma concentration assessment of simvastatin and celecoxib, which enables better treatment drug monitoring to track that prescribed medications deliver safe and effective results. The analytical system of RP-HPLC consists of respective mobile and stationary phases that differentiate between mixture components and transport the mixture through the column. (8) The therapeutic outcome of drugs depends on both drug concentration in blood and sufficient exposure duration, since insufficient drug exposure leads to therapeutic failure, but excessive drug exposure generates adverse side effects. The exposure to greater simvastatin concentrations raises the risk of developing muscle-related toxicity that could result in fatal rhabdomyolysis. At such high plasma levels of celecoxib, patients risk heightened heart attack and stroke events through blood pressure fluctuations and platelet aggregation effects. The use of RP-HPLC-based methods enables medical practitioners to measure therapeutic drug levels in plasma during combination therapy situations. (9)This method extends beyond standard therapeutic drug surveillance because it allows point-of-care measurement for both drugs at once. The evaluation of drug ADME properties in the body during pharmacokinetic studies depends critically on this technique. Research studies enable scientists to track how these drugs respond inside the human body and recognize both drug-drug interactions and modifications in pharmacokinetic properties that occur when multiple drugs are combined. (8)The discovered information enables doctors to establish proper combination therapy dosages, thus helping patients achieve better results and minimize side effects. RP-HPLC simultaneous quantitation methods of simvastatin and celecoxib serve as an analytical tool for clinical studies that evaluate the safety and effectiveness of combined drug therapy. Such investigations gain special importance when patients receive polypharmaceutical drug combinations to handle multiple coexisting conditions. Multiple drug coadministration has emerged as a standard clinical practice because chronic diseases like cardiovascular disease and arthritis now affect a greater number of patients. The assessment of exact drug combination plasma levels serves as a vital prerequisite for patients to get proper treatment, along with determining their safety outcomes.(10) The present study investigates current RP-HPLC methods that perform simultaneous analysis of simvastatin and celecoxib concentrations in plasma samples. This paper presents a detailed description of the development pathway for method optimization alongside its chromatographic parameters and requirements for method validation and practical applications. The review presents an examination of the clinical value of this method for therapeutic drug tracking and pharmacokinetic studies, as well as drug interaction evaluations. (11) It analyzes RP-HPLC technological advances to show their clinical effect on simvastatin and celecoxib combination treatment and suggests further analytical research directions. (12)The clinical benefits of using simvastatin combined with celecoxib pose difficult obstacles for precise drug monitoring systems. Plasma drug identification with RP-HPLC becomes a dependable analysis approach to resolve measurement difficulties through the simultaneous delivery of both drug results. This paper evaluates RP-HPLC's development while demonstrating its diagnostic strength for research needs, besides its utility in enhancing simvastatin and celecoxib combination administration.(13)

2. RP- HPLC METHOD DEVELOPMENT

The development of a reliable RP-HPLC system needs careful testing of simvastatin and celecoxib in plasma by optimizing chromatographic and sample processing variables, followed by validating the system. RP-HPLC acts as a useful technique for medication monitoring because it provides a detailed examination of chemically related compounds with high accuracy and sensitivity.(14) To develop an analytical method, one must select a suitable mobile phase and column type and set the optimal flow rate and spectral detection wavelength, and use standard methods to process plasma samples. Accurate drug separation and plasma sample measurement require optimized implementation of every factor.(15)

1. Selection of Chromatographic Conditions

Laboratory conditions established for chromatography operations enable both appropriate separation results and accurate measurement of simvastatin and celecoxib. (16) The three essential chromatographic elements include the mobile phase selection, combined with column selection and adjustment of flow rate and wavelength detection. Research groups need the correct adjustment of multiple interacting elements to achieve precise results because these elements create complex interrelationships during testing.(17)

2. Mobile Phase Optimization

The mobile phase functions as the vital component because it allows chromatographic compounds to separate during analysis. The mobile phase functions as a key element that allows the stationary phase-analyte interaction to occur during the process. The mobile phase base composition consists of organic solvents along with aqueous buffers. The separation efficiency, along with symmetrical peaks of simvastatin and celecoxib in RP-HPLC, depends on optimized mobile phase composition at proper pH conditions combined with selected polarity measures. (18) Acetonitrile, together with mixed water solutions, serves as the mobile phase of choice for scientists when they separate simvastatin and celecoxib. A limited addition of phosphoric acid or TFA to the aqueous solution enables enhanced peak resolution by stopping compound ionization while making the compounds more hydrophobic to boost their interactions with the stationary phase. A proper ratio adjustment of organic solvent to water phase must occur to reach peak retention times, which stop drugs from leaving the column too early. Drug separation through HPLC requires testing multiple solvent ratios and pH variations to control the compounds' ionization states because this determines their binding strength to the stationary phase. (19)

Table 1: RP-HPLC Method Validation Parameters (20)

Parameter	**Description**	**Target for Simvastatin & Celecoxib**
Accuracy	Closeness of the measured value to the true value.	95%-105 % recovery from plasma samples.
Precision	Consistency of measurements when repeated under identical conditions.	RSD < 2% for intra-day and inter-day testing.
Limit of Detection (LOD)	The lowest concentration of a compound that can be reliably detected.	~0.1 µg/mL for both simvastatin and celecoxib.
Limit of Quantification (LOQ)	The lowest concentration that can be reliably quantified.	~0.3 µg/mL for both drugs.
Linearity	The relationship between peak area and drug concentration.	$R^2 > 0.99$ for both drugs.
Robustness	Method's ability to remain unaffected by small variations in conditions.	No significant change in retention times.
Selectivity	Ability to separate target drugs from other plasma components.	No interference from plasma proteins or lipids.

3. Column Selection

Method development in RP-HPLC demands the selection of an appropriate column. The selection of C18 stationary phase columns represents the standard choice because they provide superior separation performance for both simvastatin and celecoxib. (21)The stationary phase of C18 columns incorporates octadecylsilane (ODS) packing that produces a nonpolar environment, which enables strong hydrophobic drug interactions to achieve clear peak resolution. The separation efficiency depends on the size of the particles used for column material. Analysis time improves, and pressure requirements increase as particle sizes decrease to 3 to 5 micrometers for enhanced resolution. Analysis time will rise when using longer columns because they yield superior resolution. The temperature setting of the column affects both analytical distinctness and analytical run duration of detected substances. Selection of the column depends on finding a balance between peak resolution quality and system pressure requirements, and sample retention time performance. (22)

4. Flow Rate and Detection Wavelength

Method development in RP-HPLC requires optimization of mobile phase flow rates as well. The separation quality, together with the analytical time, depends on mobile phase flow rate selection. An improper flow rate might damage compound separation, while a slow flow rate extends the analysis period without necessity. (23)The flow rate adjustment process requires optimization between efficient separation and sufficient speed, and must align with typical rates between 0.8 and 1.5 mL/min, depending on the size of the column, along with mobile phase characteristics. Australian scientists must carefully select the detection wavelength because it establishes both the sensitivity as well as selectivity of their findings. The UV absorbance spectra of simvastatin and celecoxib peaks maximally at approximately 240 nm. The selected wavelength provides effective detection capabilities for simultaneous quantitative analysis of the drugs in plasma-based samples. The sensitivity and ease of use of UV detection make it highly effective for compound monitoring since it can detect both compounds without requiring complicated derivatization procedures.(24)

5. Sample Preparation Techniques

The generation of reliable and valid RP-HPLC results depends on having an appropriate sample preparation method. During analyses, the plasma matrix disrupts identification of both simvastatin and celecoxib because it contains proteins and lipids, and various endogenous compounds. The sample preparation method begins by purifying plasma compositions of unnecessary interferences. The preparation of plasma samples for RP-HPLC analysis requires protein precipitation as the standard operation. Plasma experiences precipitation as a result of adding either acetonitrile or methanol as precipitating agents during this procedure. (25) The organic solvents that enter solution denature plasma proteins, causing all proteins to drop out of the liquid. The HPLC system requires the supernatant resulting from centrifugation to analyze the drugs. The sample purification system utilizes SPE as an added method to concentrate and purify the analytes. The drug compounds remain fixed on the stationary phase cartridge while other substances flow through. The analysts secure their compounds from the system after the cartridge finishes its operation, eliminating unwanted materials to proceed with HPLC analysis. (26) The HPLC assay gains better analytical accuracy when analysts reduce matrix effects through the application of this technique. Liquid-liquid extraction (LLE) serves as a suitable alternative to protein precipitation and SPE for particular applications. The scientist performs LLE by extracting plasma compounds into an organic solvent solution, followed by organic and aqueous solution phase separation. The extracted drugs require evaporation followed by reception of the proper solvent for their HPLC system injection. Two specific situations where liquid-liquid extraction (LLE) shows effectiveness involve working with very lipophilic compounds and removing impediments caused by matrix components. After membrane filter-based particulate removal, the plasma samples proceed to the HPLC apparatus. An analytical system stays free from blockage and receives only pure analyzed samples through the implementation of this filtering technique. (27)



Figure 1: A chromatographic representation illustrates RP-HPLC separation through which simvastatin and celecoxib separate when moving through the column with mobile phase flow. During detection, the compounds produce separate peaks that release in order of simvastatin before celecoxib.(16)

3. VALIDATION OF RP-HPLC METHODS

RP-HPLC method validation offers essential requirements to achieve reliable and reproducible, and usable analysis standards for specific purposes. A method that demonstrates proper validation ensures both accurate output and consistent measurements between laboratories working in different experimental settings. (28)Assessment of accuracy and precision, together with sensitivity and linearity, along with robustness and stability, and selectivity and specificity defines validation of an RP-HPLC method. The quantification method demonstrates reliable performance through evaluations of all these key parameters for measuring simvastatin and celecoxib in plasma samples. (29)

A. Accuracy and Precision

Accuracy refers to the closeness of the measured values to the true value or the reference standard. The accuracy determination in RP-HPLC methods requires analyzing the measured levels of simvastatin and celecoxib against standard values from reference methods or standard concentrations. The accuracy assessment of plasma samples happens through the addition of known drug amounts to plasma, then performing extraction before analysis. Plasma matrix recovery rates of tested drugs need to fall between 95% and 105% for the accuracy test.(30)

The precision element of method evaluation describes the capability of obtaining similar results from identical conditions during multiple sample experiments. The expression of precision occurs through relative standard deviation (RSD) calculations obtained from multiple measurements. The precision level can be determined by inspecting data at three concentration levels: single-day intra-day monitoring and multi-day inter-day testing, and across-operator inter-analyst observation. When RSD levels remain below 2%, it indicates high precision of the tested method. The RP-HPLC method delivers consistent and repeatable analytical findings under any situation where different analysts execute tests on different days.(31)

B. Sensitivity: LOD and LOQ

- The RP-HPLC method needs sensitivity as a key measurement to discover the minimum detectable and quantifiable concentrations of simvastatin and celecoxib. The RP-HPLC method uses the LOD and LOQ to evaluate the ability to detect and quantify the minimal concentrations of simvastatin and celecoxib.(32)
- **Limit of Detection (LOD)**: The LOD marks the minimal drug level that laboratory tests can identify, whereas quantification does not require correct precision and accuracy. The established measure for LOD determination depends on the signal-to-noise ratio (S/N) analysis that defines a minimum S/N ratio of 3:1 as an appropriate threshold. The plasma sample detection ability of methods depends on the LOD, which identifies the minimum drug trace concentration.(33)
- **Limit of Quantification (LOQ)**: A method achieves detection and quantitative capability at the LOQ set point when samples show acceptable accuracy and precision standards. The LOQ determination occurs through an S/N ratio of 10:1. A method should have a low LOQ to accurately measure drugs at low concentrations because therapeutic drug monitoring needs this functionality for patients receiving small-dose combination treatments.

Measuring simvastatin and celecoxib concentrations in plasma requires low LOD and LOQ limits because these drugs appear at reduced quantities in the biological sample, particularly among patients who take combined drugs.(34)

C. Linearity and Calibration Curve

RP-HPLC shows linear performance because it gives results that depend directly on the simvastatin and celecoxib concentrations throughout an extensive measurement range. A method demonstrates linearity through an unvarying peak area to analyte concentration relationship throughout its full calibration range.

Standard solutions consisting of increasing concentrations of simvastatin and celecoxib are used for determining method linearity through peak area measurement. The analysis produces a calibration curve through a graphical relationship between peak area and analyte concentration. Assessment of linearity depends on the correlation coefficient R^2 computation, which shows excellent results when the value reaches 1 or exceeds 0.99.(35)

The analysis requires an established calibration plot to reach precise measurement accuracy for plasma drug levels. The analyst determines unknown sample concentrations by measuring peak areas, which supports broad method accuracy. Routine checks of the calibration curve should be performed to validate measurement accuracy while the method is in operation.

D. Robustness and Stability

A well-built method proves its reliability by resisting small yet controlled changes made to experimental conditions. The reliability testing of RP-HPLC methods depends on carrying out experiments to determine method performance after minor adjustments to mobile phase composition and column temperature, and pH conditions. A robustness test analyzes one parameter at a time while keeping other aspects constant to identify any changes in results. Multiple small parameter modifications in a robust method will not affect its reliability because it shows no response to minor adjustments in its

parameters.(36)

The unmodified condition of an analyzed substance during all analytical periods constitutes analytic stability. The evaluation system conducts two checks to assess specimen drug preservation along with RP-HPLC system performance reliability across time. The scientific evaluation of simvastatin and celecoxib plasma stability requires conducting tests at diverse time intervals and temperature variables. When using the method in clinical operations, the stability of drugs should be maintained at constant levels throughout analysis periods without any impact from delayed testing.(37)

E. **Selectivity and Specificity**

A proper method based on RP-HPLC technology needs to demonstrate selectivity and specificity to identify and quantify simvastatin and celecoxib from plasma constituents, including proteins and lipids, and other metabolites. The separation power of RP-HPLC methodology pertains to its ability to divide target compounds from interfering chemicals, alongside its precise ability to identify and quantify target substances without interference from chemical cross-reactions.(38)

The RP-HPLC method demonstrates drug selectivity through an evaluation that determines its performance in discriminating simvastatin and celecoxib from plasma endogenous substances and other drugs that patients take concurrently. A technical requirement exists for the method to stop plasma proteins or lipids from impacting results, since inaccurate outcomes would occur.

The selectivity of this method is studied through plasma tests that show neither simvastatin nor celecoxib appears as peaks in the obtained results. The spiked plasma evaluation demonstrates that the method correctly identifies both medications present in mixtures of pharmaceutical compounds.(39)

4. ADVANCEMENTS IN RP-HPLC TECHNIQUES

Modern improvements in the RP-HPLC protocol (Reverse Phase High-Performance Liquid Chromatography) have improved its analytical drug assessment capacity, thus enhancing accuracy and detection efficiency as well as operational outcomes. The development of improved columns alongside mobile phase optimization and detector system optimization made RP-HPLC a highly effective bioanalytical tool that enables complete drug monitoring of simvastatin and celecoxib. Research within RP-HPLC has expanded its practical applications to pharmaceutical tests and therapeutic drug analysis, and medical research.(40, 41)

1. Innovations in Column Technology

RP-HPLC efficiencies and resolving power are primarily determined through column technology among all necessary elements. Rocking innovation in column materials and stationary phases, and packing techniques during multiple years led to performance improvements mainly affecting resolution speed and reproducibility. The creation of sub-2-micron particles for column packing stands as the main breakthrough in column technology development. Sub-2-micron particles employed in HPLC columns give rise to increased surface capacity, together with elevated resolution, which produces superior separation quality. The analyzed substances reach enhanced separation capacity when working with these columns that operate at shorter times than columns using traditional larger particles, thereby achieving improved efficiency and analytical capability. (42)The new plasma analytical equipment requires this innovation to achieve the best possible separation of target substances from background compounds. Due to their distinctive benefits, the market is moving toward core-shell particles (superficially porous particles) in growing numbers. These columns achieve sub-2-micron resolution levels while using low backpressure because they have a porous outer shell on a solid core structure. Normal operating pressures achieved through core-shell design lead to improved chromatographic separations that result in efficient analysis at low operational costs. Such separator columns achieve exceptional performance rates during the separation process of compounds similar to simvastatin and celecoxib, which contain identical chemical attributes. (43) Chromatographic science progressed when scientists developed unique stationary phases that bring both tailored features and particular selection properties. The separation capabilities of polar and nonpolar compounds improve when scientists use phase columns with cyano (CN) and phenyl and ethylpyridine functionalization. These columns enable extra analytical separation selectivity due to their additional analytical interactions, which separate similar physical components like simvastatin and celecoxib. The monolithic column represents a forward-thinking development that adds new separation options to the field of column-based technology. The development of monolithic columns as single continuous structures instead of packed particles generates valid advantages by distributing flow evenly while reducing pressure and speeding up analytical operations. The columns produce advantageous outcomes for high-throughput systems while dealing with complicated mixtures when utilized, since they facilitate fast separations and minimal operational needs, and high-resolution outputs.

2. New Developments in Mobile Phase Composition

RP-HPLC separation success depends predominantly on mobile phase formulation because new mobile phase discoveries have led to substantial development in method chromatographic performance. Recent mobile phase innovations focus on both better separation of challenging targets and method stability improvements, and reduced environmental impact. The incorporation of green solvents represents a critical advancement in chromatographic techniques since such environmentally-

friendly substances take safety factors into account. Health and environmental threats emerge from using oral organic solvents such as methanol and acetonitrile. Water-miscible ionic liquids and supercritical fluids serve as promising environmental alternatives that scientists currently employ for their research. Ionic liquids display specific properties to launch as mobile phase elements for enhancing compound separation of polar and nonpolar substances, whereas they minimize toxic waste output and decrease environmental strain. These solvents guarantee durability and improve the separation capability between target compounds, simvastatin and celecoxib, even though they typically exhibit identical polar features. Mobile phase optimization involves buffering solutions at specific pH levels that control the drug-ionization state when stationary phases become involved. The combination of phosphate buffers, acetate buffers, and TFA (trifluoroacetic acid) allows for smooth pH stability during analysis while improving both reproducibility performance and selectivity. Pharmacological separation efficiency improves through pH-controlled mobile phase optimization because it affects how simvastatin and celecoxib interact with the stationary phase and how their peak resolution evolves. Researchers have investigated mobile phase additives, including modifiers and surfactants, as a part of their studies to achieve improved separation, together with decreased interference. The separation of complex drug mixtures has achieved optimum results by optimizing variable concentrations of organic modifiers between acetonitrile, methanol, and isopropanol. A modification of the stationary phase through surfactant use in RP-HPLC enables better resolution of difficult-to-separate compounds, including simvastatin, which demonstrates weak solubility and strong hydrophobic behavior. The development of gradient elution methods continues to advance through the creation of improved techniques that enhance solvent change rates during separation procedures. The use of gradient elution as a method to change solvents during separation enhances the efficiency of compound separation, mainly for polar molecules of diverse chemical properties. The application of this method proves most useful when analyzing plasma samples containing two drugs, such as simvastatin and celecoxib, which produce different elution speeds.(44)

5. APPLICATIONS OF RP-HPLC FOR SIMVASTATIN AND CELECOXIB

Pharmaceutical and clinical research rely on RP-HPLC (Reverse Phase High-Performance Liquid Chromatography) as their primary analytical method to determine multiple drugs, including simvastatin and celecoxib, simultaneously. The precise plasma quantification of these drugs through RP-HPLC creates opportunities in pharmacokinetic research fields and therapeutic drug examinations, as well as drug interaction investigations. (45)The applications provide essential functionality for patient care because they optimize treatment plans and help comprehend drug-body interactions while maintaining patient security. (46)

5.1 Pharmacokinetic Studies and Drug Monitoring

Human body processing of drugs requires pharmacokinetic research to determine absorption dynamics alongside distribution and metabolism, and excretion behavior. RP-HPLC should be employed to measure drug plasma concentrations of simvastatin and celecoxib because it delivers essential information about drug half-life and availability, and elimination mechanisms. RP-HPLC techniques enable scientists to determine simvastatin and celecoxib plasma concentrations at different times after drug administration, which generates concentration-time curves through these data points. (47)The gathered data helps researchers compute two essential pharmacological quantities, namely Cmax (Maximum plasma concentration) and tmax (Time to reach Cmax).**Tmax** (Time to reach maximum concentration)**Half-life** (T1/2)

I. **Area Under the Curve (AUC)**, which represents the total drug exposure over time

Drug circulation parameters in blood receive vital information through the data about distribution duration in blood and the speed of drug reception and removal times. The pharmacokinetic description of simvastatin helps researchers examine liver drug processing alongside all chemical substances that interact during body absorption.(48) Both pharmacokinetic investigations determine celecoxib transport throughout the body and analyze its influence on pain reduction and inflammation pathways. The evaluation of drug concentrations throughout the bloodstream becomes effective through RP-HPLC techniques, thus making it fundamental for drug monitoring purposes. Medical professionals benefit from plasma level monitoring of simvastatin and celecoxib due to their ability to achieve maximum therapeutic outcomes with reduced side effects through appropriate drug concentration management. Plasma tests of simvastatin play a critical role in preventing rhabdomyolysis muscle toxicity since this drug exhibits limited therapeutic safety ranges. Cardiovascular and inflammatory condition patients receiving simvastatin and celecoxib need dual blood medication monitoring since improper plasma level concentrations lead to treatment failure as well as adverse reactions. Chemists use RP-HPLC technology to precisely detect two plasma-based medications at low concentrations, which enables healthcare monitoring with dose adjustment possibilities.

5.2 Therapeutic Drug Monitoring in Clinical Settings

Healthcare providers utilize therapeutic drug monitoring techniques through TDM in their clinical work to decide appropriate drug amounts that lead to beneficial outcomes while minimizing any potential adverse effects on patients. TDM benefits from RP-HPLC because this technique provides exceptional plasma-based biological specimen analysis through precise measurements. TDM enables healthcare providers to use accurate measurements of simvastatin and celecoxib drug levels in

blood to stop adverse effects and deliver optimal treatment outcomes. TDM provides clinical practice with its essential purpose to help healthcare providers adjust drug dosages in response to patient medication reactions. (49) The way drugs interact with patients depends on their age, weight, as well as liver and kidney function, together with the number of medical conditions they have. When patients suffer from liver dysfunction, the normal breakdown of simvastatin changes, which can enhance both drug concentrations and the likelihood of adverse side effects. Safety measures require physicians to decrease celecoxib doses in patients with renal dysfunction because their body takes longer to eliminate the drug, leading to elevated plasma levels and elevated cardiovascular risks. The real-time monitoring capabilities of RP-HPLC enable treatment adjustments by clinicians to better serve individual patient requirements. Medical staff use routine plasma drug concentration tests to calculate suitable drug dosages for simvastatin and celecoxib that maintain the therapeutic effectiveness of both medicines. Medical staff needs to decrease simvastatin doses when measured plasma levels reach beyond target ranges to stop potential harm to muscles or the liver. Medical staff need to modify the dosage of celecoxib when plasma tests detect insufficient concentrations that hinder treatment goals. (50)

Patients under extended combination therapy benefit from RP-HPLC-based TDM testing since it provides better surveillance of their high-risk medical condition. Plasma drug concentration tests allow medical staff to detect potential health risks that enable them to establish preventive measures to protect patients from treatment complications.

5.3 Drug Interaction Studies

The combination of simvastatin and celecoxib medications within a patient population with multiple illnesses creates suitable circumstances for possible drug substance interactions. Pharmacotherapy with multiple drugs produces three distinct drug action outcomes, from increased drug potency to reduced drug effectiveness and intensified medication side effects. Patient treatment requires drug interaction analysis for celecoxib and simvastatin to achieve the best possible results.RP-HPLC serves as a crucial tool in drug interaction analyses because it delivers exact plasma measurements of two drugs, which helps researchers interpret drug interaction patterns in concurrent drug administration. (51)The breakdown of simvastatin relies on the CYP3A4 enzyme working with the cytochrome P450 system. The exposure of simvastatin rises in plasma after antifungal or protease inhibitor exposure, which increases the risk of adverse side effects, including toxic effects on muscles. Celecoxib demonstrates a risk of cardiovascular events when used with drugs that influence both platelet aggregation and blood pressure regulation, as well as drug metabolism. RP-HPLC provides an accurate method to measure the amounts of simvastatin and celecoxib in plasma and determine their concentration changes following co-medication with additional drugs. (52)The measured data reveal changes in drug pharmacokinetics, which signify the occurrence of substantial drug interactions. Research can examine if celecoxib impacts simvastatin through plasma level assessment between patients who receive celecoxib treatment and those who do not. Laboratory analysis of celecoxib levels in patients using cardiovascular drugs enables healthcare providers to determine possible adverse drug interactions affecting the likelihood of heart attack and stroke, alongside bleeding risks. Researchers employ RP-HPLC analyses to study multiple drug impacts on the metabolic processes of both simvastatin and celecoxib during drug interaction evaluations. Researchers need this information specifically in polypharmacy because patients typically combine several different medications to treat numerous health conditions. The analysis of drug interactions enables researchers to recommend the most secure and efficient medications since these evaluations reduce negative outcomes while assuring positive patient results. (53)



Figure 2: Drawing from observational data indicates how drug interactions between simvastatin, celecoxib, and other drugs will modify plasma concentration levels as presented in the diagram. Other Drug influences both simvastatin and celecoxib concentrations following administration, while RP-HPLC assists in plasma concentration monitoring.

Table 2: Key pharmacokinetic parameters for simvastatin and celecoxib (54, 55)

Pharmacokinetic Parameter	Simvastatin	Celecoxib
Cmax (Maximum Plasma Concentration)	10-20 ng/mL (varies by dose)	5-10 µg/mL (varies by dose)
Tmax (Time to Reach Cmax)	1-2 hours	3-5 hours
Half-life (T1/2)	2-3 hours	8-12 hours
AUC (Area Under Curve)	50-100 ng·h/mL (varies by dose)	70-150 µg·h/mL (varies by dose)
Volume of Distribution (Vd)	0.5-1.0 L/kg	0.1-0.5 L/kg
Clearance (Cl)	2-3 L/h	0.2-0.4 L/h

6. CHALLENGES AND LIMITATIONS

Multiple limitations affect the effectiveness of RP-HPLC in determining both simvastatin and celecoxib drugs. Plasma matrices containing biological substances cause difficulties in precise target compound measurement because matrix interference exists. Plasma contains endogenous compounds that produce false results through measurement suppression effects while causing incorrect measurement outcomes. Determination of drug dilutions in complicated biological specimens demands exceptional sensitivity because these substances create difficulties during measurement processes. (56)HPLC systems operate under constraints that stem from technological specifications and operational control factors. The operation of RP-HPLC systems equipped with high-resolution and mass spectrometry detection requires both regular upkeep and the performance of calibration procedures and proper procedural care.(56) The operational needs generate technical barriers because of the requirements to manage high-pressure systems while maintaining tight variable control. Advanced, skilled operators are needed to maintain these systems, create supplementary operational and maintenance challenges within the method. Deciding elements for operations include the total expenses and potential scalability. RPC-HPLC needs substantial funding because expensive equipment, measurement units, coupled with sophisticated column assemblies and detection systems, and solution solvents generate high expenses. Standard clinical practices cannot utilize the technology due to its excessively costly operating expenses. Mass production of this method demands substantial financial investment, together with operational delays for equipment and procedures, which reduces its usefulness when economic efficiency and rapid sample analysis are needed.(57)

7. CONCLUSION

RP-HPLC demonstrates its ability to analyze plasma samples containing simvastatin alongside celecoxib because of its precise detection methods. The technique provides essential pharmacokinetic research methods that assist both therapeutic drug monitoring processes and drug interaction evaluations to help optimize patient safety through optimized treatments. Contemporary developments in chromatographic procedures and the improvement of columns alongside detection techniques have led medical research laboratories to achieve better efficiency through this method. The upcoming stages of RP-HPLC development must focus on both mass spectrometry-based detection enhancements and selectivity improvements alongside environmental sustainability advancements. RP-HPLC accessibility and efficiency need effective solutions that address matrix interference and scalability, and cost concerns above all, to develop clinical applications sufficiently. Constant technique development will enhance RP-HPLC functionality to monitor drug safety levels and maximize both simvastatin and celecoxib and other medication use.

REFERENCES

[1] Jiang W, Hu J-W, He X-R, Jin W-L, He X-Y. Statins: a repurposed drug to fight cancer. Journal of Experimental & Clinical Cancer Research. 2021;40(1):241.

[2] Shi Z, Han S. Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins. Heliyon. 2025;11(1):e41629.

[3] Khatiwada N, Hong Z. Potential Benefits and Risks Associated with the Use of Statins. Pharmaceutics. 2024;16(2):214.

[4] Rawat C, Kukal S, Dahiya UR, Kukreti R. Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management. Journal of Neuroinflammation. 2019;16(1):197.

[5] Brune K, Neubert A. Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: A

pharmacologist's perspective. Clinical and experimental rheumatology. 2001;19:S51-7.

[6] Dunn SP, Holmes DR, Moliterno DJ. Drug–Drug Interactions in Cardiovascular Catheterizations and Interventions. JACC: Cardiovascular Interventions. 2012;5(12):1195-208.

[7] Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22(4):310-8.

[8] Puszkiel A, Noé G, Boudou-Rouquette P, Cossec C, Jennifer A, Giraud J-S, et al. Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis. 2017;139.

[9] Alhajj M, Zubair M, Farhana A. Enzyme-Linked Immunosorbent Assay. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.

[10] Naidu R, Kale U, Shingare M. Stability indicating RP-HPLC method for simultaneous determination of amlodipine and benzapril hydrochloride from their combination drug product. Journal of pharmaceutical and biomedical analysis. 2005;39:147-55.

[11] Gumułka P, Żandarek J, Dąbrowska M, Starek M. UPLC Technique in Pharmacy—An Important Tool of the Modern Analyst. Processes. 2022;10(12):2498.

[12] Gehrke T, Scherzad A, Hackenberg S, Ickrath P, Schendzielorz P, Hagen R, et al. Additive antitumor effects of celecoxib and simvastatin on head and neck squamous cell carcinoma in vitro. Int J Oncol. 2017;51(3):931-8.

[13] Tome T, Casar Z, Obreza A. Development of a Unified Reversed-Phase HPLC Method for Efficient Determination of EP and USP Process-Related Impurities in Celecoxib Using Analytical Quality by Design Principles. Molecules (Basel, Switzerland). 2020;25.

[14] Tome T, Časar Z, Obreza A. Development of a Unified Reversed-Phase HPLC Method for Efficient Determination of EP and USP Process-Related Impurities in Celecoxib Using Analytical Quality by Design Principles. Molecules. 2020;25(4).

[15] Marques Marinho F. Development and Validation of an RP-HPLC Method for Simvastatin Capsules. Current Pharmaceutical Analysis. 2013;9:2-12.

[16] Tome T, Žigart N, Časar Z, Obreza A. Development and Optimization of Liquid Chromatography Analytical Methods by Using AQbD Principles: Overview and Recent Advances. Organic Process Research & Development. 2019;23(9):1784-802.

[17] Aljammal K. Development and Validation of Micro Emulsion High Performance Liquid Chromatography(MELC) Method for the Determination of Nifedipine in Pharmaceutical Preparation. Pharmaceutica Analytica Acta. 2015;06.

[18] Mahadevarao Premnath S, Zubair M. Chromatography. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.

[19] Djajić N, Krmar J, Rmandić M, Rašević M, Otašević B, Zečević M, et al. Modified aqueous mobile phases: A way to improve retention behavior of active pharmaceutical compounds and their impurities in liquid chromatography. Journal of Chromatography Open. 2022;2:100023.

[20] Dey S, De A, Mandal S, Pradhan P, Patel C, Shah S, et al. DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF SIMVASTATIN IN BULK AND PHARMACEUTICAL DOSAGE FORM. 2013:3.

[21] Žuvela P, Skoczylas M, Liu J, Bączek T, Kaliszan R, Wong M, et al. Column Characterization and Selection Systems in Reversed-Phase High-Performance Liquid Chromatography. Chemical Reviews. 2019;119.

[22] Attimarad M, Venugopala KN, Sreeharsha N, Chohan MS, Shafi S, Nair AB, et al. A Rapid HPLC Method for the Concurrent Determination of Several Antihypertensive Drugs from Binary and Ternary Formulations. Separations. 2021;8(6):86.

[23] Alphonse M, Nesrine L. Experimental design methodology for optimization and robustness determination in ion pair RP-HPLC method development: Application for the simultaneous determination of metformin hydrochloride, alogliptin benzoate, and repaglinide in tablets. Microchemical Journal. 2019;147.

[24] Agrahari V, Bajpai M, Nanda S. Essential Concepts of Mobile Phase Selection for Reversed Phase HPLC. Research Journal of Pharmacy and Technology. 2013;6:459-64.

[25] Tripathi DA, Dewani A, Chandewar A, Mazumder PM. Approaches development and validation of RP-HPLC method for estimation of glimepiride in rat plasma-application to pharmacokinetic studies. 2016;11:55-61.

[26] Eveque-Mourroux MR, Emans PJ, Boonen A, Claes BSR, Bouwman FG, Heeren RMA, et al. Heterogeneity of

Lipid and Protein Cartilage Profiles Associated with Human Osteoarthritis with or without Type 2 Diabetes Mellitus. Journal of Proteome Research. 2021;20(5):2973-82.

[27] Badawy MEI, El-Nouby MAM, Kimani PK, Lim LW, Rabea EI. A review of the modern principles and applications of solid-phase extraction techniques in chromatographic analysis. Analytical Sciences. 2022;38(12):1457-87.

[28] Paithankar H. HPLC METHOD VALIDATION FOR PHARMACEUTICALS: A REVIEW. International Journal of Universal Pharmacy and Biosciences. 2013;2:229-40.

[29] Veeran MG, C K, B B, Painuly D, Aprem AS. RP-HPLC method validation for fast extraction and quantification of Levonorgestrel drug from silicone based intrauterine device intended for in-process and finished formulation. Daru. 2021;29(1):185-93.

[30] Betz JM, Brown PN, Roman MC. Accuracy, precision, and reliability of chemical measurements in natural products research. Fitoterapia. 2011;82(1):44-52.

[31] Vitorino C, Sousa J, Pais A. A rapid reversed-phase HPLC method for the simultaneous analysis of olanzapine and simvastatin in dual nanostructured lipid carriers. Analytical Methods. 2013;5:5058.

[32] Nalaiya J, Sagineedu S, Rajasingam R, Zawahil K, Pichika M. A Stability-indicating RP-HPLC method for simultaneous determination of simvastatin and niacin in a combined dosage form. International Journal of Pharmacy and Pharmaceutical Sciences. 2014;7:262-8.

[33] Dixit RP, Barhate CR, Padhye SG, Viswanathan CL, Nagarsenker MS. Stability Indicating RP-HPLC Method for Simultaneous Determination of Simvastatin and Ezetimibe from Tablet Dosage Form. Indian J Pharm Sci. 2010;72(2):204-10.

[34] Tome T, Obreza A, Časar Z. Developing an Improved UHPLC Method for Efficient Determination of European Pharmacopeia Process-Related Impurities in Ropinirole Hydrochloride Using Analytical Quality by Design Principles. Molecules. 2020;25(11):2691.

[35] Ashour S, Omar S. New Validated Analytical Method for Determination of Simvastatin in Tablet Formulations by RP–HPLC. Drug and Drug Abuse. 2020:1-8.

[36] Trivedi N, Tandel D, Patel K, Parmar R, Patel G, Gandhi T. Stability indicating HPTLC method development and validation for simultaneous analysis of Levodropropizine and Chlorpheniramine Maleate in syrup formulation. Discover Chemistry. 2025;2(1):52.

[37] Ferreira S, Caires A, Borges T, Lima A, Silva L, Santos W. Robustness evaluation in analytical methods optimized using experimental designs. Microchemical Journal. 2016;131.

[38] Gandu S, Gandla K. Development of a quality by design-based ultra-performance liquid chromatography method for the simultaneous estimation of casirivimab and imdevimab with greenness metrics. Green Analytical Chemistry. 2025;13:100248.

[39] Urmi KF, Nawaz MS, Islam SMA. Analytical quality by design approach to RP-HPLC method development and validation for simultaneous estimation of esomeprazole and naproxen in modified-release dosage form. Future Journal of Pharmaceutical Sciences. 2022;8(1):8.

[40] Kako D, Ghareeb MM, Al-Lami MS. High-Performance Liquid Chromatography (HPLC) Method Validation for Identifying and Quantifying Rebamipide in Ethosomes. Cureus. 2024;16(3):e56061.

[41] Aboushady D, Samir L, Masoud A, Elshoura Y, Mohamed A, Hanafi RS, et al. Chemometric Approaches for Sustainable Pharmaceutical Analysis Using Liquid Chromatography. Chemistry. 2025;7(1):11.

[42] Smith N, Jiang Z. Developments in the use and fabrication of organic monolithic phases for use with high-performance liquid chromatography and capillary electrochromatography. Journal of chromatography A. 2008;1184:416-40.

[43] Nema T, Chun Yong Chan E, Ho P. Applications of monolithic materials for sample preparation. Journal of pharmaceutical and biomedical analysis. 2013;87.

[44] Pund S, Nalawade S, Rajurkar V, Jayatpal S, Deshmukh N, Tare H. A brief review on recent advances in reverse phase HPLC. Multidisciplinary Reviews. 2024;7:2024072.

[45] Rashad EA, Elsayed SS, Nasr JJM, Ibrahim FA. Improved fast reversed-phase HPLC using factorial design for concurrent analysis of ramipril, atorvastatin, and clopidogrel in laboratory synthesized tablet. Microchemical Journal. 2025;210:112804.

[46] Mozayad AN, Fouad MA, Elkady EF. Utilizing experimental design and desirability function in optimizing RP-HPLC method for simultaneous determination of some skeletal muscle relaxants and analgesics. Scientific Reports. 2024;14(1):10360.

[47] Rower J, Bushman L, Hammond K, Kadam R, Aquilante C. Validation of a LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study. Biomedical chromatography : BMC. 2010;24:1300-8.

[48] Neaz S, Alam MM, Imran AB. Advancements in cyclodextrin-based controlled drug delivery: Insights into pharmacokinetic and pharmacodynamic profiles. Heliyon. 2024;10(21).

[49] Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1-10.

[50] Lim S-N, Wu T, Chang C-W, Johnny Tseng W-E, Cheng M-Y, Hsieh H-Y, et al. Clinical impact of therapeutic drug monitoring for newer anti-seizure medications in patients with epilepsy: A real-world observation study. Biomedical Journal. 2024;47(5):100680.

[51] Wang J, Chi CL, St Peter WL, Carlson A, Loth M, Pradhan PM, et al. A Population-Based Study of Simvastatin Drug-Drug Interactions in Cardiovascular Disease Patients. AMIA Jt Summits Transl Sci Proc. 2020;2020:664-73.

[52] Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, et al. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Target Oncol. 2019;14(5):527-39.

[53] Hîncu S, Apetroaei M-M, Ștefan G, Fâcă AI, Arsene AL, Mahler B, et al. Drug–Drug Interactions in Nosocomial Infections: An Updated Review for Clinicians. Pharmaceutics. 2024;16(9):1137.

[54] Moon SJ, Lee S, Jang K, Yu KS, Yim SV, Kim BH. Comparative pharmacokinetic and tolerability evaluation of two simvastatin 20 mg formulations in healthy Korean male volunteers. Transl Clin Pharmacol. 2017;25(1):10-4.

[55] Krishna R, Garg A, Jin B, Keshavarz SS, Bieberdorf FA, Chodakewitz J, et al. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009;67(5):520-6.

[56] Preeti, Sambhakar S, Saharan R, Narwal S, Malik R, Gahlot V, et al. Exploring LIPIDs for their potential to improves bioavailability of lipophilic drugs candidates: A review. Saudi Pharm J. 2023;31(12):101870.

[57] Gomes F, García P, Alves J, Singh A, Kedor-Hackmann E, Santoro M. Development and Validation of Stability-Indicating HPLC Methods for Quantitative Determination of Pravastatin, Fluvastatin, Atorvastatin, and Rosuvastatin in Pharmaceuticals. Analytical Letters - ANAL LETT. 2009;42:1784-804.